Company Filing History:
Years Active: 2003
Title: The Innovative Contributions of Helen Logothetou-Rella
Introduction
Helen Logothetou-Rella is a notable inventor based in Athens, Greece. He has made significant contributions to the field of pharmaceutical preparations, particularly in tumor therapy. His work focuses on the use of calcium-activated neutral protease (CANP) inhibitors, which have potential applications in cancer treatment.
Latest Patents
Helen Logothetou-Rella holds 1 patent for his invention titled "Use of calcium-activated neutral protease (CANP) inhibitors in pharmaceutical preparations." This invention provides a method for utilizing inhibitors of calcium-activated neutral proteases and their pharmaceutically acceptable addition salts or active subunits in tumor therapy. The inhibitors are particularly effective against protease-bound glycosaminoglycan substrate-dependent tumors and meiotic cell division. The invention includes heat-stable, tetrameric proteins of approximately 240 kD and tripeptides that exhibit inhibitory activity. The pharmaceutical compositions can be prepared using common carriers or additives in the pharmaceutical industry.
Career Highlights
Helen Logothetou-Rella is associated with Norsk Hydro, A.S., where he applies his expertise in the development of innovative pharmaceutical solutions. His work at the company reflects his commitment to advancing cancer therapy through scientific research and innovation.
Collaborations
(Section skipped due to space constraints.)
Conclusion
Helen Logothetou-Rella's contributions to the field of pharmaceutical preparations highlight the importance of innovation in cancer therapy. His work with CANP inhibitors represents a significant advancement in the fight against tumors.